Obagi Medical Products Inc trades in the stock market as ticker OMPI. Business Summary & Profile For Obagi Medical Products Inc.

Obagi Medical Products Inc

Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets topical aesthetic and therapeutic prescription skin care systems. It offers Obagi Nu-Derm System, including prescription and OTC drugs that are used for the treatment of fine lines, wrinkles, acne, photo-damage, hyperpigmentation, melasma, laxity, and skin sallowness; Obagi Condition and Enhance Systems that are used before and after surgical and non-surgical cosmetic procedures; Obagi-C Rx System comprises Vitamin C serum with 4% hydroquinone system for the treatment of fine lines, wrinkles, hyperpigmentation, and skin sallowness; and Professional-C products consisting of Vitamin C serums for the treatment of fine lines, wrinkles, and hyperpigmentation, as well as for antioxidant protection. The company also provides ELASTIderm Eye and D├ęcolletage, which increase the elasticity and skin tone of eyes, face, neckline, and chest; ELASTILash Eyelash Solution that enhances the appearance of thickness and fullness of eyelashes; CLENZIderm M.D. Systems used for the treatment of acne; Obagi Rosaclear System used for the treatment of rosacea; and Tretinoin used for the treatment of acne. In addition, it offers Refissa used for the treatment of fine facial lines, hyperpigmentation, and tactile roughness; Metronidazole used for the treatment of rosacea; Obagi Blue Peel Essential Kit used for the treatment of fine lines, wrinkles, and hyperpigmentation; and Blue Peel RADIANCE used for the treatment of fine facial lines, hyperpigmentation, and tactile roughness. Further, the company licenses OTC product systems to Japanese based pharmaceutical companies for sale in Japan under the Obagi trademark. Obagi Medical Products, Inc. sells its products through own domestic sales force and foreign distributors to dermatologists, plastic surgeons, and other physicians that are focused on aesthetic and therapeutic skin care. The company was founded in 1988 and is headquartered in Long Beach, California.
www.obagi.com
203 Employees
Last Reported Date: 03/11/11
Founded in 1988
LAST $11.85 USD
CHANGE TODAY +0.23 1.98%
VOLUME 79.9K
As of 5:20 PM 02/23/12 All times are local (Market data is delayed by at least 15 minutes).

Snapshot of OBAGI MEDICAL PRODUCTS INC (OMPI)

OPEN
$11.63
PREVIOUS CLOSE
$11.62
DAY HIGH
$11.90
DAY LOW
$11.56
52 WEEK HIGH
04/26/11 - $13.00
52 WEEK LOW
05/6/11 - $8.61
MARKET CAP
220.4M
AVERAGE VOLUME 10 D
192.7K
EPS TTM
$0.82
SHARES OUTSTANDING
18.6M
OMPI Does Not Pay Dividends
P/E TTM
14.5x
K = Thousands  M = Millions  B = Billions

related news

No related news articles were found.

related news for OBAGI MEDICAL PRODUCTS INC (OMPI)

Analyst Picks and Pans: AmEx, JPMorgan, H.B. Fuller

Key developments for OBAGI MEDICAL PRODUCTS INC (OMPI)

Voce Asks Obagi To Consider Multiple Alternatives

Voce Capital Management, LLC has sent a letter to the Board of Directors of Obagi Medical Products, Inc. criticizing their recent adoption of a poison pill and demanding immediate action to address corporate governance deficiencies and to evaluate strategic alternatives. Voce Capital calls upon the Board of Obagi to immediately commence a review of their strategic alternatives, including good faith consideration of the strong strategic interest in acquiring Obagi; overhaul the Obagi Board, including the removal of Directors Fitzgibbons and Bartholdson and their replacement with proper independent shareholder representation.

Obagi Medical Products, Inc. Introduces Two New Line Extension Products

Obagi Medical Products, Inc. announced new additions to two of its clinically proven product lines: ELASTIderm Eye Complete Complex Serum(TM) and CLENZIderm M.D. Normal to Oily System. ELASTIderm Eye Complete Complex Serum is the latest member of the ELASTIderm Eye family of products. The Complete Complex Serum is formulated with a proprietary bi-mineral complex and malonic acid, which in combination have been shown to improve the appearance of fine lines and wrinkles around the eye. The innovative stainless steel rollerball applicator provides a soothing effect and optimized delivery of the Serum to assist in improving the appearance of puffiness under the eye. Used twice daily for best results, ELASTIderm Eye Complete Complex Serum also includes caffeine to energize the skin under the eye. In a recent study, consumers reported that the results met or exceeded their expectations, stating that the ELASTIderm Eye Complete Complex Serum was better than the eye product they were currently using. Additionally, the new and improved CLENZIderm M.D. Normal to Oily System is now available, joining the existing Normal to Dry System. The system includes Daily Care Foaming Cleanser (2% salicylic acid), Pore Therapy (2% salicylic acid) and Therapeutic Lotion (5% benzoyl peroxide) for clear skin, fast. This new System is clinically proven to deliver clearer, healthier skin in just two weeks.

Obagi Medical Products, Inc. Presents at Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference, Dec-06-2011 02:00 PM

Obagi Medical Products, Inc. Presents at Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference, Dec-06-2011 02:00 PM. Venue: St. Regis Hotel, 125 3rd Street, San Francisco, CA 94103, United States. Speakers: Preston S. Romm, Chief Financial Officer, Principal Accounting Officer, Executive Vice President of Finance, Operations & Administration.

OMPI Competitors

Company Last Change
Cynosure Inc $17.78 USD +0.16
Palomar Medical Technologies Inc $10.87 USD +0.10
PhotoMedex Inc $13.10 USD +0.20
Solta Medical Inc $2.76 USD -0.03
Spectranetics Corp $8.68 USD +0.36
Market data is delayed at least 15 minutes.
 

Industry Analysis

Valuation OMPI Industry Range
Price/Earnings 28.4x
Price/Sales 1.9x
Price/Book 3.9x
Price/Cash Flow 27.6x
Not meaningful
TEV/Sales 1.7x

OMPI

 | 

OMPI transactions

Type
Date
Target
No transactions in the last 6 months.
OBAGI MEDICAL PRODUCTS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delist
  Read More...
Valeant completes tender offer for Obagi Medical
  Read More...
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
[CNW Group] - Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
  Read More...
Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
[CNW Group] - Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
  Read More...
4 Healthcare Stock Stories Prescribed for Investors
  Read More...
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
[CNW Group] - Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
  Read More...
Valeant Receives Antitrust Clearance for Obagi Purchase
  Read More...
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
[CNW Group] - Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
  Read More...
Gabelli raises stake in Obagi Medical to 12.17% from 11.14%
  Read More...
[video] The Five Dumbest Things on Wall Street: April 12
  Read More...

Write Comment Create Account

Quotes are delayed for NASDAQ, NYSE, OTC, OTCBB (Penny Stocks) and NYSE Amex when available. Quotes and other information supplied by independent providers and feeds. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Localnewsnor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing Localnews, you agree not to redistribute the information found therein.

Privacy Policy - WE KEEP YOUR PERSONAL DATA PRIVATE AND CONFIDENTIAL - Localnews is committed to protecting the privacy of all our visitors and subscribers. Your right to privacy is very important to us. When you choose to provide us with information about yourself, we recognize that you trust us to act in a responsible manner. SHARING OF INFORMATION - Localnews does not sell, rent, lease or share any user information that it has collected over this website.

@2012 www.localnewsnow.org - Contact Us / Privacy Policy